Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the experimental immunotherapy agent cemiplimab-rwlc
when given after completion of chemotherapy and radiation treatment and determine if it will
improve progression free survival and cure rates in patients with PD-L1 positive locally
advanced head and neck cancer.